Compare NRSN & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRSN | CCM |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4M | 23.8M |
| IPO Year | 2021 | 2009 |
| Metric | NRSN | CCM |
|---|---|---|
| Price | $0.96 | $4.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 320.8K | 11.6K |
| Earning Date | 04-06-2026 | 09-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,056,841.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.68 | $3.54 |
| 52 Week High | $2.60 | $10.77 |
| Indicator | NRSN | CCM |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 52.28 |
| Support Level | $0.86 | $3.80 |
| Resistance Level | $1.08 | $5.17 |
| Average True Range (ATR) | 0.10 | 0.67 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 58.35 | 38.27 |
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.